StimAire replaces today's surgically implanted neural stimulation devices with a small wearable and a tiny injectable device. The technology will eliminate major surgery and associated complications, risks, and costs. The total market opportunity for StimAire's neural stimulation is tens of billions of dollars and includes treatments for obstructive sleep apnea (OSA), bladder control, epilepsy, Parkinson's and central and peripheral pain.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
11/18/19 | undisclosed |
UAVenture Capital | undisclosed |